ULTIO Stock Overview
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Ultimovacs ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr102.00 |
| 52 Week High | kr160.80 |
| 52 Week Low | kr71.20 |
| Beta | 1.18 |
| 1 Month Change | 13.33% |
| 3 Month Change | n/a |
| 1 Year Change | 31.44% |
| 3 Year Change | 101.58% |
| 5 Year Change | n/a |
| Change since IPO | 234.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| ULTIO | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -7.3% | 3.6% | 1.1% |
| 1Y | 31.4% | -3.2% | 8.6% |
Return vs Industry: ULTIO exceeded the Swedish Biotechs industry which returned -2.8% over the past year.
Return vs Market: ULTIO exceeded the Swedish Market which returned 5.8% over the past year.
Price Volatility
| ULTIO volatility | |
|---|---|
| ULTIO Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in SE Market | 13.5% |
| 10% least volatile stocks in SE Market | 3.6% |
Stable Share Price: ULTIO's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine ULTIO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 24 | Carlos de Sousa | www.ultimovacs.com |
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers. Its lead product candidate is UV1, a peptide-based cancer vaccine that induces a specific T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.
Ultimovacs ASA Fundamentals Summary
| ULTIO fundamental statistics | |
|---|---|
| Market cap | kr3.60b |
| Earnings (TTM) | -kr186.30m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-19.3x
P/E RatioIs ULTIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ULTIO income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr186.30m |
| Earnings | -kr186.30m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Nov 08, 2023
| Earnings per share (EPS) | -5.42 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ULTIO perform over the long term?
See historical performance and comparison